BOSTON--(BUSINESS WIRE)-- Gilead Sciences, Inc. (Nasdaq: GILD) today announced new data from the open-label phase of two pivotal Phase III clinical trials (Studies 102 and 103) evaluating the ...
Gilead (GILD)'s HIV drug Viread already carries a warning for loss of bone density, among many others, but a rash of recent studies suggests the FDA should require its much more serious "black box" ...
Pharmacokinetic data from the GS-US-174-0144 trial has been added to the labeling The labeling for Viread (tenofovir disoproxil fumarate; Gilead Sciences) has been updated to include use in chronic ...
Gilead Sciences Says Viread Meets Goal in Hepatitis B Trial FOSTER CITY, Calif. -- Gilead Sciences, Inc. today announced that Study 102, a Phase III clinical trial evaluating the company's once-daily ...
The good news: The FDA approved Viread, Gilead's dwindling HIV treatment, as a therapy for hepatitis B. The drug's sales had gone down to $613 million from a peak of $783 million as newer combination ...
Gilead Sciences, Inc.Patrick O’Brien, +1 650-522-1936 (Investors)Stephen Head, +44 (208) 587-2359 (Media, Europe)Cara Miller, +1 650-522-1616 (Media, U.S.) Gilead Sciences, Inc. (Nasdaq: GILD) today ...
Tenofovir disoproxil fumarate 40mg per 1g pwd. Test for HBV and HIV-1 infection prior to initiation. May use tabs or oral pwd (if unable to swallow). Mix oral pwd with 2–4oz of soft food not requiring ...
Gilead Sciences Inc. dropped the price of its HIV-fighting drug Viread by nearly 37 percent for patients in 68 developing nations where the Foster City firm started offering the drug at no profit last ...
To earn CME related to this news article, click here. February 18, 2009 — The US Food and Drug Administration (FDA) has approved safety labeling revisions to warn of the risk for potentially fatal ...
Often in business and life, an important conversation, a made or missed connection, or even an intrusion of pure fate redirects our thinking and actions for years afterward. Forbes is asking leaders ...
LOS ANGELES, June 6 (Reuters) - Gilead Sciences Inc. said on Wednesday that a late-stage clinical trial showed its HIV drug Viread met its main goal of reducing viral levels and liver inflammation in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results